Keywords: پمترکسید، آلیمتا; NSCLC; Brain metastases; Pemetrexed; Stereotactic; Necrosis;
مقالات ISI پمترکسید، آلیمتا (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پمترکسید، آلیمتا; Metronomic chemotherapy; Oral anticancer; Low-dose therapy; Drug delivery; Pemetrexed; Lung cancer; Bile acids;
Keywords: پمترکسید، آلیمتا; AICA; 5-aminoimidazole-4-carboxamide; AICARFTase; 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; CA; carbonic anhydrase; CBE; CI-HCO3â exchanger; CHO; Chinese hamster ovary; FR; folate receptor; GARFTase; β-glycinamide ribonucleotide
Keywords: پمترکسید، آلیمتا; BSC; best supportive care; EORTC; European Organisation for Research and Treatment of Cancer; EPP; extrapleural pneumonectomy; IMIG; International Mesothelioma Interest Group; MPM; malignant pleural mesothelioma; PEM; pemetrexed; PD; pleurectomy decortica
Keywords: پمترکسید، آلیمتا; Elderly; Meta-analysis; Advanced non-small cell lung cancer; Pemetrexed; Overall survival;
Keywords: پمترکسید، آلیمتا; Cytoreductive surgery; Hyperthermic perioperative chemotherapy (HIPEC); Early postoperative intraperitoneal chemotherapy (EPIC); Normothermic intraperitoneal chemotherapy (NIPEC); Cisplatin; Doxorubicin; Paclitaxel; Pemetrexed; Intraperitoneal port; Tenck
Keywords: پمترکسید، آلیمتا; CTD; connective tissue diseases; LC; lung cancer; SLE; systemic lupus erythematosus; PM/DM; polymyositis/dermatomyositis; SSc; systemic sclerosis; ILD; interstitial lung disease; IPF; idiopathic pulmonary fibrosis; AE; acute exacerbation; PS; performance
Keywords: پمترکسید، آلیمتا; Non-small cell lung cancer; Chemotherapy; Second-line treatment; Docetaxel; Pemetrexed; Erlotinib;
Keywords: پمترکسید، آلیمتا; Malignant pleural mesothelioma (MPM); Cisplatin derivatives; Cationic platinum complex; Pemetrexed; Mesenchymal stromal cells (MSC);
Keywords: پمترکسید، آلیمتا; Peritoneal mesothelioma; HIPEC; Cytoreductive surgery; Pemetrexed; Pharmacokinetics;
Keywords: پمترکسید، آلیمتا; Prognostic factors; Malignant mesothelioma; Pemetrexed; CALGB scoring system; EORTC scoring system
Keywords: پمترکسید، آلیمتا; Nanoparticles; Doxorubicin; Vinblastine; Imatinib; Pemetrexed; Chitosan; Emulsion; Tumor; Cancer; Anticancer; P-gp; Efflux;
Keywords: پمترکسید، آلیمتا; Fmoc; fluorenylmethyloxycarbonyl; FPGS; folylpoly-gamma glutamase synthase; MSNT; 1-(2- mesitylenesulfonyl)-3-nitro-1H-1,2,4-triazole; PMTX; pemetrexed; PMTXPG1; Pemetrexed-monoglutamic acid; PMTXPG2; pemetrexed-diglutamic acid; PMTXPG3; pemetrexed-triglu
Keywords: پمترکسید، آلیمتا; Lung adenocarcinomas; Bevacizumab; Nonplatinum chemotherapy; Pemetrexed; Paclitaxel;
Keywords: پمترکسید، آلیمتا; Non-small cell lung cancer; Macrocytosis; Mean corpuscular volume; Pemetrexed; Prognostic; Predictive role;
Keywords: پمترکسید، آلیمتا; Renal insufficiency; Bevacizumab; Pemetrexed; Non-small cell lung cancer;
Keywords: پمترکسید، آلیمتا; Anaplastic lymphoma kinase (ALK); Driver oncogene; Epidermal growth factor receptor (EGFR); KRAS; Non–small-cell lung cancer; NRAS; Pemetrexed; ROS1
Keywords: پمترکسید، آلیمتا; Malignant pleural mesothelioma; Pemetrexed; Liposomes; Orthotopic tumor model; Intrapleural administration;
Keywords: پمترکسید، آلیمتا; Metastatic breast cancer; Chemotherapy; Pemetrexed; Anthracycline; Taxane
Keywords: پمترکسید، آلیمتا; Creatinine clearance rate; Maintenance therapy; Non-small cell lung cancer; Pemetrexed; Treatment effectiveness/toxicity;
Keywords: پمترکسید، آلیمتا; Squalene-based nanocarriers; Vegetale fractions; Dual drug delivery; Pemetrexed; Hesperidin
Keywords: پمترکسید، آلیمتا; Malignant pleural mesothelioma; Cisplatin; Gemcitabine; Pemetrexed; Chemotherapy;
Keywords: پمترکسید، آلیمتا; Non–small-cell lung cancer; Pemetrexed; p53; Glucocorticoid receptor
Keywords: پمترکسید، آلیمتا; Non-squamous non-small cell lung cancer; Pemetrexed; Gefitinib; Cisplatin; East Asian patients
Keywords: پمترکسید، آلیمتا; NSCLC; Pemetrexed; Cisplatin; Radiotherapy; Induction; Phase I trial;
Keywords: پمترکسید، آلیمتا; Pemetrexed; Cost effectiveness; Paclitaxel; Bevacizumab; Non-small cell lung cancer; Survival outcomes;
Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial
Keywords: پمترکسید، آلیمتا; Pemetrexed; Non-squamous non-small cell lung cancer; Fatigue; Quality of life (QoL); East asian;
Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506)
Keywords: پمترکسید، آلیمتا; ALK; anaplastic lymphoma kinase; CI; confidence interval; CTONG; Chinese Thoracic Oncology Group; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; MERAF; Medical Record Abstraction Form; NSCLC; non-small cell lung cancer;
Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum
Keywords: پمترکسید، آلیمتا; Non-squamous non-small-cell lung cancer; DNA repair; Single nucleotide polymorphism; Pemetrexed; Platinum;
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)
Keywords: پمترکسید، آلیمتا; Neoadjuvant treatment; Lung cancer; NSCLC; Pemetrexed; Carboplatin;
Lung cancer specific and reduction-responsive chimaeric polymersomes for highly efficient loading of pemetrexed and targeted suppression of lung tumor in vivo
Keywords: پمترکسید، آلیمتا; Polymersomes; Reduction-sensitive; Targeted delivery; Pemetrexed; Lung cancer;
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Keywords: پمترکسید، آلیمتا; ROS1; Crizotinib; Pemetrexed; Carcinoma; Non-small cell lung cancer;
High and individually variable enzymatic activity precludes accurate determination of pemetrexed, methotrexate and their polyglutamate metabolite concentrations in plasma
Keywords: پمترکسید، آلیمتا; MTX; methotrexate; MTXPG1; methotrexate monoglutamate; MTXPG2; methotrexate diglutamate; MTXPG3; methotrexate triglutamate; PMTX; pemetrexed; PMTXPG1; pemetrexed monoglutamate; PMTXPG2; pemetrexed diglutamate; PMTXPG3; pemetrexed triglutamate; Mass spectr
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
Keywords: پمترکسید، آلیمتا; NSCLC; Non-small cell lung cancer; EGFR; Epidermal growth factor receptor; OS; Overall survival; PD; Progressive disease; PFS; Progression-free survival; Gefitinib; Pemetrexed; EGFR mutation; Beyond progressive disease;
The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC
Keywords: پمترکسید، آلیمتا; NSCLC; Pemetrexed; Positron-emission tomography; Staging;
Dexamethasone alleviates pemetrexed-induced senescence in Non-Small-Cell Lung Cancer
Keywords: پمترکسید، آلیمتا; Senescence-associated secretory phenotype; Pemetrexed; Dexamethasone; Cancer stem cells; Non-small cell lung cancer;
Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells
Keywords: پمترکسید، آلیمتا; Mesenchymal stromal cells; Mesothelioma; Paclitaxel; Pemetrexed; Cell drug delivery;
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous nonâsmall cell lung cancer
Keywords: پمترکسید، آلیمتا; CHK1; selective inhibitor of checkpoint kinase 1; LY + Pem + Cis; LY2603618 + pemetrexed + cisplatin; Pem + Cis; pemetrexed + cisplatin; Checkpoint kinase 1; Cisplatin; Pemetrexed; LY2603618; Non-small cell lung cancer;
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Keywords: پمترکسید، آلیمتا; Cixutumumab; IMC-A12; First-line therapy; Pemetrexed; NSCLC;
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Keywords: پمترکسید، آلیمتا; Bevacizumab; Chemotherapy; Lung cancer; Maintenance therapy; Pemetrexed;
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1
Keywords: پمترکسید، آلیمتا; LC; lung cancer; ILD; interstitial lung disease; HRCT; high-resolution computed tomography; AE; acute exacerbation; DAD; diffuse alveolar damage; IPF; idiopathic pulmonary fibrosis; PS; performance status; ECOG; Eastern Cooperative Oncology Group; NSCLC;
Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer
Keywords: پمترکسید، آلیمتا; Non-small cell lung cancer (NSCLC); Maintenance; Pemetrexed; Treatment discontinuation;
In situ-prepared homogeneous supramolecular organic framework drug delivery systems (sof-DDSs): Overcoming cancer multidrug resistance and controlled release
Keywords: پمترکسید، آلیمتا; Supramolecular organic framework; In situ preparation; Drug delivery; Controlled release; Pemetrexed; Human breast cancer; Multidrug resistance;
Original ResearchA phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients wi
Keywords: پمترکسید، آلیمتا; Phosphatidylinositol 3-kinase; Non-small cell lung; Bevacizumab; Paclitaxel; Carboplatin; Cisplatin; Pemetrexed; Metastatic NSCLC; Front-line NSCLC; First-line NSCLC;
Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B12 and Folate Supplementation in Nonsquamous, Non-Small-cell Lung Cancer Patients Undergoing First-line Pemetrexed-based Chem
Keywords: پمترکسید، آلیمتا; Folic acid; Pemetrexed; Supplementation; Toxicity; Vitamin B12;
The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: Hereditary folate malabsorption
Keywords: پمترکسید، آلیمتا; Proton-coupled folate transporter; PCFT; SLC46A1; Reduced folate carrier; RFC; SLC19A1; Folate receptors; FRα; Folates; Folic acid; Methotrexate; Pemetrexed; Hereditary folate malabsorption; HFM; Cerebral folate deficiency; CFD; 5-Formyltetrahydrofolate
Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents
Keywords: پمترکسید، آلیمتا; Multiple receptor tyrosine kinase inhibitors; Antiangiogenic agents; Pyrimido[4,5-b]indole synthesis; Thymidylate synthase inhibitors; Combination chemotherapeutic potential in single agents; RTK; receptor tyrosine kinases; VEGF; vascular endothelial grow
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
Keywords: پمترکسید، آلیمتا; Mesothelioma; Cediranib; Cisplatin; Pemetrexed;
CE method for the in-process control of the synthesis of active substances conjugated with gold nanoparticles
Keywords: پمترکسید، آلیمتا; Capillary electrophoresis; In-process control; Validation; Pemetrexed; Genistein;
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer
Keywords: پمترکسید، آلیمتا; Lung adenocarcinoma; ROS1; Concomitant mutations; EGFR; Pemetrexed;